API XML

Aop: 223

AOP Title

?


Serotonin transporter activation to seizure

Short name:

?

Serotonin transporter activation to seizure

Graphical Representation

?

Click to download graphical representation template

Authors

?


Point of Contact

?


Lyle Burgoon   (email point of contact)

Contributors

?


  • Hsin-Yen Wu
  • Edward Perkins
  • Lyle Burgoon

Status

?

Author status OECD status OECD project SAAOP status
Under development: Not open for comment. Do not cite Under Development


This AOP was last modified on July 24, 2017 15:22

?

Revision dates for related pages

Page Revision Date/Time
Increased, extracellular serotonin May 31, 2017 16:48
Decreased, extracellular serotonin May 31, 2017 16:46
Increased, seizure June 01, 2017 11:55
Increased, serotonin transporter activity June 01, 2017 14:51
Increased, intracellular serotonin June 01, 2017 14:51
Increased, packaged serotonin June 01, 2017 14:52
Increased, synaptic release June 01, 2017 14:53
Decreased, 5-HT3 June 01, 2017 14:54
Increased, serotonin transporter activity leads to Increased, intracellular serotonin June 01, 2017 14:55
Increased, intracellular serotonin leads to Increased, packaged serotonin June 01, 2017 14:55
Increased, packaged serotonin leads to Increased, synaptic release June 01, 2017 14:56
Increased, synaptic release leads to Increased, extracellular serotonin June 01, 2017 14:56
Increased, serotonin transporter activity leads to Decreased, extracellular serotonin June 01, 2017 14:56
Increased, extracellular serotonin leads to Decreased, 5-HT3 June 01, 2017 14:57
Decreased, 5-HT3 leads to Increased, seizure June 01, 2017 14:58
serotonin transporter activation June 01, 2017 11:53

Abstract

?



Background (optional)

?


Larry: The serotonin transporter may be repressed by SSRI, thus extracellular serotonin is increased and seizure is reduced. However, I did not add this "SSRI inhibits serotonin transporter" relationship into the AOP since SSRI inhibition does not contribute directly to the AOP (It modified the MIE "the activation of serotonin transporter"), but it certainly could be a modifier to prevent the adverse outcome.


Summary of the AOP

?


Events: Molecular Initiating Events (MIE)

?

Key Events (KE)

?

Adverse Outcomes (AO)

?

Sequence Type Event ID Title Short name
1 MIE 1397 Increased, serotonin transporter activity Increased, serotonin transporter activity
2 KE 1320 Increased, extracellular serotonin Increased, extracellular serotonin
3 KE 1347 Decreased, extracellular serotonin Decreased, extracellular serotonin
4 KE 1398 Increased, intracellular serotonin Increased, intracellular serotonin
5 KE 1399 Increased, packaged serotonin Increased, packaged serotonin
6 KE 1400 Increased, synaptic release Increased, synaptic release
7 KE 1401 Decreased, 5-HT3 Decreased, 5-HT3
8 AO 1344 Increased, seizure Increased, seizure

Relationships Between Two Key Events
(Including MIEs and AOs)

?

Title Adjacency Evidence Quantitative Understanding
Increased, serotonin transporter activity leads to Increased, intracellular serotonin adjacent
Increased, intracellular serotonin leads to Increased, packaged serotonin adjacent
Increased, packaged serotonin leads to Increased, synaptic release adjacent
Increased, synaptic release leads to Increased, extracellular serotonin adjacent
Increased, serotonin transporter activity leads to Decreased, extracellular serotonin adjacent
Increased, extracellular serotonin leads to Decreased, 5-HT3 adjacent
Decreased, 5-HT3 leads to Increased, seizure adjacent

Network View

?

 

Stressors

?

Life Stage Applicability

?

Taxonomic Applicability

?

Sex Applicability

?

Overall Assessment of the AOP

?



Domain of Applicability

?


Essentiality of the Key Events

?


Evidence Assessment

?


Quantitative Understanding

?


Considerations for Potential Applications of the AOP (optional)

?



References

?